title: Evaluation of myocardial function using the Tei index in patients with Kawasaki disease.
abstract: Myocarditis is a well-recognized component of Kawasaki disease, with left ventricular dysfunction occurring in more than half of the patients during the acute phase of the disease. The purpose of our study was to evaluate myocardial function in these patients using the myocardial performance index, also known as the Tei index. In a prospective study, 14 patients underwent echocardiographic evaluation, first at the time of diagnosis of the disease, in its acute phase before treatment with intravenous immunoglobulin and then 2 weeks later after treatment with immunoglobulin. We assessed the Tei-index, the ejection fraction, shortening fraction, and the presence of valvar regurgitation, pericardial effusion, or coronary arterial involvement. As a control, we also assessed 22 healthy children, matched for age and sex with the study population. Of the patients, half had an increased left ventricular Tei-index in the acute phase, as compared with the data obtained after treatment, the index changing from 0.43 +/- 0.08 to 0.35 +/- 0.06 (p equal to 0.003). An increased index for the right ventricle was found in 5 patients (36%), values being 0.30 +/- 0.05 as opposed to 0.26 +/- 0.04 (p equal to 0.009). Of the patients, 5 (35.7%) also had decreased ejection fractions and proportional shortening fractions during the acute phase, confirming left ventricular dysfunction. We concluded that the Tei-index, which measures combined systolic and diastolic function, is a simple, sensitive, and accurate tool for estimating global myocardial dysfunction in patients with Kawasaki disease.
authors.affiliation: Divisions of Pediatric Cardiology and Immunology, Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran. ajamigh@sums.ac.ir
authors.forename: Gholamhossein
authors.initials: G
authors.lastname: Ajami
authors.forename: Mohammad
authors.initials: M
authors.lastname: Borzouee
authors.forename: Hamid
authors.initials: H
authors.lastname: Amoozgar
authors.forename: Feridoon
authors.initials: F
authors.lastname: Ashnaee
authors.forename: Sara
authors.initials: S
authors.lastname: Kashef
authors.forename: Mir Sabina
authors.initials: MS
authors.lastname: Nesar
authors.forename: Mir Soleh
authors.initials: MS
authors.lastname: Nesar
mesh_terms: D000704:Analysis of Variance; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003326:Coronary Circulation / Q000502:physiology; D003971:Diastole / Q000502:physiology; D015150:Echocardiography, Doppler; D005260:Female; D006334:Heart Function Tests; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D008297:Male; D008944:Mitral Valve Insufficiency / Q000000981:diagnostic imaging / Q000503:physiopathology; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D009200:Myocardial Contraction / Q000502:physiology*; D009205:Myocarditis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D011336:Probability; D011379:Prognosis; D012016:Reference Values; D012720:Severity of Illness Index; D013318:Stroke Volume; D018615:Ultrasonography, Doppler, Color; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology
chemical_list: D007136:Immunoglobulins